Next Science Limited (NXS.AX)
| Previous close | 0.7700 |
| Open | 0.7700 |
| Bid | 0.7500 x 853200 |
| Ask | 0.7600 x 1877300 |
| Day's range | 0.7500 - 0.7700 |
| 52-week range | 0.7000 - 1.7000 |
| Volume | |
| Avg. volume | 100,121 |
| Market cap | 161.092M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against Both Planktonic Bacteria and Bacterial Biofilms
JACKSONVILLE, Fla., May 10, 2022--Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty. The study, "A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty," also found that XPERIENCE produced minima
- Business Wire
Next Science to Exhibit Surgical Product Portfolio at AAOS 2021
JACKSONVILLE, Fla., August 24, 2021--Next Science Limited (ASX:NXS) announced that it will exhibit at the AAOS annual meeting and conference in San Diego, Calif., from Aug. 31 – Sept. 3.
- Business Wire
Next Science Begins U.S. Clinical Trial for XPERIENCE No Rinse Antimicrobial Solution
JACKSONVILLE, Fla., August 11, 2021--Next Science Limited (ASX:NXS) announces that a U.S. clinical trial has been initiated for XPERIENCE No Rinse Antimicrobial Solution.
